跳至主要内容
临床试验/NCT07246681
NCT07246681进行中(未招募)3 期

Role of Lignin in Treatment of Helicobacter Pylori Infection: A Double-blind Placebo-controlled Study

Zagazig University1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2025年10月31日最近更新:
干预措施

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
70
试验地点
1
主要终点
Eradication rate

研究概览

简要总结

The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are:

  • Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori?
  • What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori.

Participants will:

  • Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy
  • Visit the clinic once every 1 week for checkup and questionnaire filling
  • Check for H pylori eradication after treatment

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: Adults, older than
  • Gender: all
  • Patient with confirmed diagnosis of H pylori for the first time
  • H pylori treatment naive patients
  • Welling to participate

排除标准

  • Patients with failed H pylori eradication
  • Allergy to the used medications
  • Patients with other structural bowel diseases e.g. celiac disease, ischemic colitis, IBD, chronic diarrhea
  • General debilitating diseases e.g. decompensated cirrhosis, renal failure

研究组 & 干预措施

Group I

Active Comparator

This is the study group who will receive the standard triple (proton pump inhibitor, amoxicillin, clarithromycin) therapy plus the hydrolyzed lignin 400 mg

干预措施: Hydrolyzed Lignin (Drug)

Group II

Placebo Comparator

This is the study group who will receive the standard triple therapy (proton pump inhibitor, amoxicillin, clarithromycin) plus the placebo identical in color, shape, and taste with the hydrolyzed lignin

干预措施: Placebo (Other)

结局指标

主要结局

Eradication rate

时间窗: 2 weeks of continuous treatment, followed by 2 weeks of treatment and then testing again for presence\absence of the infection

How much the H pylori eradication rate following the treatment

次要结局

  • Safety profile(up to 4 weeks (2 weeks active treatment and 2 weeks after treatment))

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验